Combination chemotherapy for influenza

Viruses

Volumn 2, Issue 8, 2010, Pages 1510-1529

  Govorkova, Elena A ^a   Webster, Robert G ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Amantadine; Antivirals; Combination therapy; Influenza virus; Neuraminidase inhibitors; Oseltamivir; Ribavirin

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ALPHA INTERFERON; AMANTADINE; APROTININ; CYANOVIRIN N; DAS 181; FAVIPIRAVIR; FLUDASE; LANINAMIVIR OCTANOATE; OSELTAMIVIR; PERAMIVIR; PLACEBO; PROBENECID; RAPIACTA; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; COMBINATION CHEMOTHERAPY; CYTOPATHOGENIC EFFECT; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SENSITIVITY; DRUG TOLERABILITY; HEPATITIS C; HONG KONG INFLUENZA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; INFLUENZA; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA A (H9N2); INFLUENZA B; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PROTEIN PROTEIN INTERACTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ORTHOMYXOVIRIDAE;

EID: 79251559935     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2081510     Document Type: Review

References (76)

1. Stephenson, I.; Nicholson, K.G. Influenza: vaccination and treatment. Eur. Respir. J. 2001, 17, 1282-1293.
2. Ong, A.K.; Hayden, F.G.; John F. Enders lecture 2006: Antivirals for influenza. J. Infect. Dis. 2007, 196, 181-190.
3. Moscona, A. Medical management of influenza infection. Annu. Rev. Med. 2008, 59, 397-413.
4. Bright, R.A.; Medina, M.J.; Xu, X.; Perez-Oronoz, G.; Wallis, T.R.; Davis, X.M.; Povinelli, L.; Cox, N.J.; Klimov, A.I. Incidence of amantadine resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause of concern. Lancet 2005, 366, 1175-1181.
5. Deyde, V.M.; Xu, X.; Bright, R.A.; Shaw, M.; Smith, C.B.; Zhang, Y.; Shu, Y.; Gubareva, L.V.; Cox, N.J.; Klimov, A.I. Surveillance of resistance to adamantanes among influenza A (H3N2) and A (H1N1) viruses isolated worldwide. J. Infect. Dis. 2007, 196, 249-257.
6. Hurt, A.C.; Selleck, P.; Komadina, N.; Shaw, R.; Brown, L.; Barr, I.G. Susceptibility of highly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 2007, 73, 228-231.
7. Gubareva, L.; Okomo-Adhiambo, M.; Deyde, V.; Fry, A.M.; Sheu, T.G.; Garten, R.; Smith, D.C.; Barnes, J.; Myrick, A.; Hillman, M.; Shaw, M.; Bridges, C.; Klimov, A.; Cox, N. Centers for Disease Control and Prevention (CDC). Update: Drug susceptibility of swine origin influenza A (H1N1) viruses, April 2009. MMWR Morb. Mortal. Wkly Rep. 2009, 58, 433-435.
8. Ferraris, O.; Lina, B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J. Clin. Virol. 2008, 41, 13-19.
9. Herlocher, M.L.; Carr, J.; Ives, J.; Elias, S.; Truscon, R.; Roberts, N.; Monto, A.S. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 2002, 54, 99-111.
10. Yen, H-L; Herlocher, L.M.; Hoffmann, E.; Matrosovich, M.N.; Monto, A.S.; Webster, R.G.; Govorkova, E.A. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 2005, 49, 4075-4084.
11. Bouvier, N.M.; Lowen, A.C.; Palese, P. Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J. Virol. 2008, 82, 10052-10058.
12. Ward, P.; Small, I.; Smith, J.; Suter, P.; Dutkowski, R. Oseltamivir (TamifluR) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 2005, 55, 5-21.
13. Lackenby, A.; Hungnes, O.; Dudman, S.G.; Meijer, A.; Paget, W.J.; Hay, A. J.; Zambon, M.C. Emergence of resistance to oseltamivir among influenza A (H1N1) viruses in Europe. Eurosurveillance 2008, 13, 1-3.
14. Dharan, N.J.; Gubareva, L.V.; Meyer, J.J.; Okomo-Adhiambo, M.; McClinton, R.C.; Marshall, S.A.; George, K. St.; Epperson, S.; Brammer, L.; Klimov, A.I.; Bresee, J.S.; Fry, A.M. For the Oseltamivir-Resistance Working Group. Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. JAMA 2009, 301, 1034-1041.
15. Hurt, A.C.; Ernest, J.; Deng, Y-M.; Iannello, P.; Besselaar, T.G.; Birch, C.; Buchy, P.; Chittaganpitch, M.; Chiu, S-C.; Dwyer, D.; Guigoni, A.; Harrower, B.; Kei, I.P.; Kok, T.; Lin, C.; McPhie, K.; Mohd, A.; Olveda, R.; Panayotou, T.; Rawlinson, W.; Scott, L.; Smith, D.; D'Souza, H.; Komadina, N.; Shaw, R.; Kelso, A.; Barr, I.G. Emergence and spread of oseltamivir-resistant A (H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 2009, 83, 90-93.
16. Bautista, E.; Chotpitayasunondh, T.; Gao, Z.; Harper, S.A.; Shaw, M.; Uyeki, T.M.; Zaki, S.R.; Hayden, F.G.; Hui, D.S.; Kettner, J.D.; Kumar, A.; Lim, M.; Shindo, N.; Penn, C.; Nicholson, K.G. Writing Committee of the WHO Consultation on the Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N. Engl. J. Med. 2010, 362, 1708-1719.
17. Li, I.W.; Hung, I.F.; To, K.K.; Chan, K.H.; Wong, S.S.; Chan, J.F.; Cheng, V.C.; Tsang, O.T.; Lai, S.T.; Lau, Y.L.; Yuen, K.Y. The natural viral load profile of patients with pandemic 2009 influenza A (H1N1) and the effect of oseltamivir treatment. Chest 2010, 137, 759-768.
18. Ling, L.M.; Chow, A.L.; Lye, D.C.; Tan, A.S.; Krishnan, P.; Cui, L.; Win, N.N.; Chan, M.; Lim, P.L.; Lee, C.C.; Leo, Y.S. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin. Infect. Dis. 2010, 50, 963-969.
19. Gulick, R. Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents. AIDS 1998, 12, S17-22.
20. Raboud, J.M.; Harris, M.; Rae, S.; Montaner, J.S. Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Med. 2002, 3, 118-124.
21. Suhnel, J. Evaluation of synergism or antagonism for the combined action of antiviral agents. Antiviral Res. 1990, 13, 23-40.
22. Galegov, G.A.; Pushkarskaya, N.L.; Obrosova-Serova, N.P.; Zhdanov, V.M. Combined action of ribavirin and rimantadine in experimental myxovirus infection. Experientia 1977, 33, 905-906.
23. de Clercq, E. Antiviral agents active against influenza A viruses. Nature Rev. 2006, 5, 1015-1025.
24. Sidwell, R.W.; Bailey, K.W.; Wong, M.H.; Barnard, D.L.; Smee, D.F. In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res. 2005, 68, 10-17.
25. Smee, D.F.; Wong, M.H.; Bailey, K.W.; Sidwell, R.W. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antiviral Chem. Chemother. 2006, 17, 185-192.
26. Hayden, F.G.; Douglas, R.G., Jr.; Simons, R. Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob. Agents Chemother. 1980, 18, 536-541.
27. Hayden, F.G.; Slepushkin, A.N.; Pushkarskaya, N.L. Combined interferon-α2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro. Antimicrob. Agents Chemother. 1984, 25, 53-57.
28. Shigeta, S.; Mori, S.; Watanabe, J.; Soeda, S.; Takahashi, K.; Yamase, T. Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo. Antimicrob. Agents Chemother. 1997, 41, 1423-1427.
29. Serkedjieva J. Combined antiinfluenza virus activity of Flos verbasci infusion and amantadine derivatives. Phytother. Res. 2000, 14, 571-574.
30. Gegova, G.; Manolova, N.; Serkedzhieva, Iu.; Maksimova, V.; Uzunov, S.; Dzeguze, D.; Indulen, M. Combined effect of selected antiviral substances of natural and synthetic origin. II. Anti-influenza activity of a combination of a polyphenolic complex isolated from Geranium sanguineum L. and rimantadine in vivo. Acta Microbiol Bulg. 1993, 30, 37-40.
31. Kim, C.U.; Lew, W.; Williams, M.A.; Liu, H.; Zhang, L.; Swaminathan, S.; Bischofberger, N.; Chen, M.S.; Mendel, D.B.; Tai, C.Y.; Laver, W.G.; Stevens R.C. Influenza neuraminidase inhibitors possessing a novel hydrophobic interactions in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 1997, 119, 681-690.
32. von Itzstein, M.; Wu, W.-Y.; Kok, G.K.; Pegg, M.S.; Dyason, J.C.; Jin, B.; Van Phan, T.; Smithe, M.L.; White, H.F.; Oliver, S.W.; Colman, P.M.; Varghese, J.N.; Ryan, D.M.; Woods, J.M.; Bethell, R.C.; Hotham, V.J.; Cameron, J.M.; Penn, C.R. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363, 418-423.
33. Babu, Y.S.; Chand, P.; Bantia, S.; Kotian, P.L.; Dehghani, A.; El-Kattan, Y.; Lin, T.; Hutchison, T.L.; Elliot, A.J.; Parker, C.D.; Ananth, S.L.; Horn, L.L.; Laver, G.W.; Montgomery, J.A. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 2000, 43, 3482-3486.
34. Madren, L.K.; Shipman, C., Jr.; Hayden, F.G. In vitro inhibitory effects of combinations of anti-influenza agents. Antivir. Chem. Chemother. 1995, 6, 109-113.
35. Smee, D.F.; Bailey, K.W.; Morrison, A.C.; Sidwell, R.W. Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 2002, 48, 88-93.
36. Govorkova, E.A.; Fang, H.B.; Tan, M.; Webster, R.G. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob. Agents Chemother. 2004, 48, 4855-4863.
37. Ilyushina, N.A.; Bovin, N.V.; Webster, R.G.; Govorkova, E.A. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res. 2006, 70, 121-131.
38. Smee, D.F.; Hurst, B.L.; Wong, M.H.; Bailey, K.W.; Morrey, J.D. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob. Agents Chemother. 2009, 53, 2120-2128.
39. Nguyen, J.T.; Hoopes, J.D.; Le, M.H.; Smee, D.F.; Patick, A.K.; Faix, D.J.; Blair, P.J.; de Jong M.D.; Prichard, M.N.; Went, G.T. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010, 5, e9332.
40. Nguyen, J.T.; Hoopes, J.D.; Smee, D.F.; Prichard, M.N.; Driebe, E.M.; Engelthaler, D.M.; Le, M.H.; Keim, P.S.; Spence, R.P.; Went, G.T. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob. Agents Chemother. 2009, 53, 4115-4126.
41. Prichard, M.N.; Shipman, C., Jr. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 1990, 14, 181-206.
42. Galabov, A.S.; Simeonova, L.; Gegova, G. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice. Antivir. Chem. Chemother. 2006, 17, 251-258.
43. Ilyushina, N.A.; Hoffmann, E.; Salomon, R.; Webster, R.G.; Govorkova, E.A. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antiviral Ther. 2007, 12, 363-370.
44. Ilyushina, N.A.; Hay, A.; Yilmaz, N.; Boon, A.C.M.; Webster, R.G.; Govorkova, E.A. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob. Agents Chemother. 2008, 52, 3889-3897.
45. Masihi, K.N.; Schweiger, B.; Finsterbusch, T.; Hengel, H. Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infection in mice. J. Chemother. 2007, 19, 295-303.
46. Wilson, S.Z.; Knight, V.; Wyde, P.R.; Drake, S.; Couch, R.B. Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob. Agents Chemother. 1980, 17, 642-648.
47. Hayden, F.G. Combinations of antiviral agents for treatment of influenza virus infections. J. Antimicrob. Chemother. 1986, 18, 77-83.
48. Zhirnov, O.P. High protection of animals lethally infected with influenza virus by aprotinin-rimantadine combinations. J. Med. Virol. 1987, 21, 161-167.
49. Peiris, J.S.M.; de Jong, M.D.; Guan, Y. Avian influenza virus (H5N1): a threat to human health. Clin. Mircob. Rev. 2007, 20, 243-267.
50. Leneva, I.A.; Roberts, N.; Govorkova, E.A.; Goloubeva, O.G.; Webster, R.G. The neuraminidase inhibitor GS 4101 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. 2000, 48, 101-115.
51. Ison, M.G.; Gnann, J.W., Jr.; Nagy-Agren, S.; Treannor, J.; Paya, C.; Steigbigel, R.; Elliott, M.; Weiss, H.L.; Hayden, F.G. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antiviral Ther. 2003, 8, 183-190.
52. Morrison, D.; Roy, S.; Rayner, C.; Amer, A.; Howard, D.; Smith, J.R.; Evans, T.G. A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS One 2007, 2, e1305.
53. Hill, G.; Cihlar, T.; Oo, C.; Ho, E.S.; Prior, K.; Wiltshire, H.; Barrett, J.; Liu, B.; Ward, P. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab. Dispos. 2002, 30, 1 3-19.
54. Holodniy, M.; Penzak, S.R.; Straight, T.M.; Davey, R.T.; Lee, K.K.; Goetz, M.B.; Raisch, D.W.; Cunningham, F.; Lin, E.T.; Olivo, N.; Deyton, L.R. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob. Agents Chemother. 2008, 52, 3013-3021.
55. De Bony, F.; Tod, M.; Bidault, R.; On, N.T.; Posner, J.; Rolan, P. Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir. Antimicrob. Agents Chemother. 2002, 46, 458-463.
56. Markowitz, J.S.; Devane, C.L.; Liston, H.L.; Boulton, D.W.; Risch, S.C. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers. Clin. Pharmacol. Ther. 2002, 71, 30-38.
57. Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.; Egawa, H.; Minami, S.; Watanabe, Y.; Narita, H.; Shiraki, K. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 2002, 46, 977-981.
58. Furuta, Y.; Takahashi, K.; Kuno-Maekawa, M.; Sangawa, H.; Uehara, S.; Kozaki, K.; Nomura, N.; Egawa, H.; Shiraki, K. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 2005, 49, 981-986.
59. Streeter, D.G.; Witkowski, J.T.; Khare, G.P.; Sidwell, R.W.; Bauer, R.J.; Robins, R.K.; Simon, L.N. Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. U S A 1973, 70, 1174-1178.
60. Smee, D.F.; Hurst, B.L.; Wong, M.H.; Bailey, K.W.; Tarbet, E.B.; Morrey, J.D.; Furuta, Y. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza a virus infections in mice. Antimicrob. Agents Chemother. 2010, 54, 126-133.
61. Chan, M.C.; Cheung, C.Y.; Chui, W.H.; Tsao, S.W.; Nicholls, J.M.; Chan, Y.O.; Chan, R.W.; Long, H.T.; Poon, L.L.; Guan, Y.; Peiris, J.S. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir. Res. 2005, 11, 1-135.
62. de Jong, M.D.; Simmons, C.P.; Thanh, T.T.; Hien, V.M.; Smith, G.J.; Chau, T.N.; Hoang, D.M.; Chau, N.V.; Khanh, T.H.; Dong, V.C.; Qui, P.T.; Cam, B.V.; Ha, do Q.; Guan, Y.; Peiris, J.S.; Chinh, N.T.; Hien, T.T.; Farrar, J. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 2006, 12, 1203-1207.
63. Zheng, B.J.; Chan, K.W.; Lin, Y.P.; Zhao, G.Y.; Chan, C.; Zhang, H.J.; Chen, H.L.; Wong, S.S.; Lau, S.K.; Woo, P.C.; Chan, K.H.; Jin, D.Y.; Yuen, K.Y. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc. Natl. Acad Sci. U S A 2008, 105, 8091-8096.
64. Ghezzi, P.; Ungheri, D. Synergistic combination of N-acetylcysteine and ribavirin to protect from lethal influenza viral infection in a mouse model. Int. J. Immunopathol. Pharmacol. 2004, 17, 99-102.
65. Garozzo, A.; Tempera, G.; Ungheri, D.; Timpanaro, R.; Castro, A. N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection. Int. J. Immunopathol. Pharmacol. 2007, 20, 349-354.
66. Serkedjieva, J.; Ivanova, E. Combined protective effect of an immunostimulatory bacterial preparation and rimantadine in experimental influenza A virus infection. Acta Virol. 1997, 41, 65-70.
67. Kohno, S.; Yen, M.Y.; Cheong, H.J.; Hirotsu, N.; Ishida, T.; Kadota, J.; Mizuguchi, M.; Kida, H.; Shimada, J. Single-intravenous peramivir vs. oral oseltamivir to treat acute, uncomplicated influenza in the outpatient setting: a phase III randomized, double-blind trial. In Proceedings of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September 2009.
68. Glaxo Smith Kline. An open-label, multi-center, single arm study to evaluate the safety and tolerability of intravenous zanamivir in the treatment of hospitalized adult, adolescent and pediatric subjects with confirmed influenza infection. Available online: http://www.gsk-clinicalstudyregister.com/protocol_detail.jsp?protocolId=113678&studyId=29102&compound=Zanamivir (accessed on 20 April 2010).
69. Kubo, S.; Tomozawa, T.; Kakuta, M.; Tokumitsu, A.; Yamashita, M. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob. Agents Chemother. 2010, 54, 1256-1264.
70. Kiso, M.; Kubo, S.; Ozawa, M.; Le, Q.M.; Nidom, C.A.; Yamashita, M.; Kawaoka, Y. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog. 2010, 6, e1000786.
71. Biota Holdings. LANI phase II completed-phase III scheduled (press release 2008). Available online: http://www.biota.com.au/uploaded/154/1021393_18laniphaseiicompleted3Dp.pdf (accessed on 20 April 2010).
72. Sugaya, N.; Ohashi, Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob. Agents Chemother. 2010, 54, 2575-2582.
73. Malakhov, M.P.; Aschenbrenner, L.M.; Smee, D.F.; Wandersee, M.K.; Sidwell, R.W.; Gubareva, L.V.; Mishin, V.P.; Hayden, F.G.; Kim, D.H.; Ing, A.; Campbell, E.R.; Yu, M.; Fang, F. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob. Agents Chemother. 2006, 50, 1470-1479.
74. Belser, J.A.; Lu, X.; Szretter, K.J.; Jin, X.; Aschenbrenner, L.M.; Lee, A.; Hawley, S.; Kim, do H.; Malakhov, M.P.; Yu, M.; Fang, F.; Katz, J.M. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J. Infect. Dis. 2007, 196, 1493-1499.
75. NexBio. NexBio Initiates Phase II Trial of DAS181 (Fludase®*) for Treatment of Influenza, Including Pandemic Influenza A (H1N1), 2010. Available online: http://www.nexbio.com/docs/DAS181_Phase_2_Press_Release_010710.pdf (accessed on 20 April 2010).
76. O'Keefe, B.R.; Smee, D.F.; Turpin, J.A.; Saucedo, C.J.; Gustafson, K.R.; Mori, T.; Blakeslee, D.; Buckheit, R.; Boyd, M.R. Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob. Agents Chemother. 2003, 47, 2518-2525.